Ambien CR vs. Placebo For Treatment Of Insomnia Associated With Anxiety When Used Concomitantly With Escitalopram (Lexapro)

Sanofi

Status and phase

Completed

Phase 4

Conditions

Insomnia

Treatments

Drug: zolpidem tartrate

Study type

Interventional

Funder types

Industry

Identifiers

NCT00296790

PM_L_0167

Details and patient eligibility

About

A comparison of Zolpidem Tartrate Extended-Release (Ambien CR)vs. Placebo in the Treatment of Insomnia Associated with Generalized Anxiety Disorder (GAD) when Used Concomitantly with Escitalopram (Lexapro - antidepressant).

Sex

All

Ages

21 to 64 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

INCLUSION CRITERIA:

Male or female between the ages of 21and 64 years, inclusive;
Women must use a medically acceptable form of contraception during the entire study period, or: be surgically sterilized, post-menopausal, agree to use double-barrier contraception throughout the study period, or must have a negative urine pregnancy test prior to randomization;
Must meet the diagnostic requirements of Generalized Anxiety Disorder as defined by the Diagnostic and Statistical Manual of Mental Disorders;
Score at least 18 on the Hamilton Rating Scale for Anxiety (HAM-A)
Must be either newly diagnosed or show symptoms of relapse during a period of no drug therapy for anxiety.
Subject must experience sleep disturbances at least three nights per week, for at least one month prior to study entry, based on historical data.
Subject must be stabilized on all long-term medication therapy for at least one month prior to study entry.

EXCLUSION

History of Post-Traumatic Stress Disorder;
Concomitant Major Depressive Disorder or Bipolar Disorder;
Any abnormal pre-study laboratory values that require clinical intervention
Shift work or requirement for a regular change in sleep schedule by at least six hours within the previous month.
Pregnant or breastfeeding
History of drug addiction, alcoholism, or drug abuse
Currently using a benzodiazepine or SSRI or more than 2 days of use within the 28 days preceding randomization.
A positive urine drug screen for compounds that would interfere with the assessment of a hypnotic.
Use of prescription and non-prescription sedative drugs;
Prior failure to respond to escitalopram therapy for anxiety
The presence of any untreated or uncompensated clinically significant renal, endocrine, gastrointestinal, hepatic, respiratory, cardiovascular, other neurologic, hematologic, oncologic, immunologic, cerebrovascular disease or malignancy.
History of sleep apnea
History of myasthenia gravis
Known hypersensitivity and/or allergy to or previous adverse experience with zolpidem or escitalopram or any of their excipients
Subject is currently participating in another clinical trial (or within 28 days of screening).